Tag Archives: NASDAQ:SAGE

The President & CEO of SAGE Therapeutics (NASDAQ: SAGE) is Buying Shares

Yesterday, the President & CEO of SAGE Therapeutics (SAGE – Research Report), Jeffrey Jonas, bought shares of SAGE for $481.5K. This recent transaction increases Jeffrey Jonas’ holding in the company by 15.95% to a total of $3.45 million. In addition

The CSO of SAGE Therapeutics is Exercising Options

Yesterday it was reported that the CSO of SAGE Therapeutics (SAGE – Research Report), Albert Robichaud, exercised options to buy 15,743 SAGE shares at $20.11 a share, for a total transaction value of $316.7K. Following Albert Robichaud’s last SAGE Buy

Cowen & Co. Keeps a Buy Rating on SAGE Therapeutics (SAGE)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $96.00. The company’s shares closed last Monday at $61.02, close to its 52-week low of $56.50.

Morgan Stanley Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) on November 21 and set a price target of $217.00. The company’s shares closed last Monday at $149.00. According to TipRanks.com, Harrison is a

H.C. Wainwright Initiates a Hold Rating on SAGE Therapeutics (SAGE)

SAGE Therapeutics (SAGE – Research Report) received a Hold rating and a $160.00 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed last Monday at $140.16. According to TipRanks.com, Tsao is a 1-star analyst with an

Oppenheimer Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $170. The company’s shares closed on Friday at $167.34, close to its 52-week high of